Ajax Therapeutics, Inc. announced that it will receive $95,000,000 in funding on April 26, 2024. The company will issue common shares in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.92 USD | -2.10% |
|
-10.79% | -47.12% |
05-13 | Ajax Therapeutics, Inc. announced that it has received $95 million in funding from a group of investors | CI |
05-07 | Ansys Partners With Schrodinger to Accelerate Materials Development | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
899.7 USD | +0.93% | +1.99% | 803B | ||
455.9 USD | -0.34% | +2.10% | 155B | ||
18.92 USD | -2.10% | -10.79% | 1.4B | ||
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.12% | 1.4B | |
+18.34% | 3,317B | |
+19.91% | 95.04B | |
+18.43% | 89.51B | |
+52.27% | 57.5B | |
-20.85% | 49.11B | |
+36.56% | 48.55B | |
+86.10% | 43.81B | |
-34.59% | 39.87B | |
-3.64% | 27.19B |
- Stock Market
- Equities
- SDGR Stock
- News Schrödinger, Inc.
- Ajax Therapeutics, Inc. announced that it expects to receive $95 million in funding